* 40 new Amgen molecules are currently being developed
Amgen, global leader in biotechnology and personalized therapies, annually invests a quarter of its turnover for developing innovative medicines and biosimilars.
“Last year, Amgen invested over USD 5 billion in the research and development of new products. At present, we are currently developing 40 biologic therapies and 6 biosimilar products. Two of the molecules are cancer treatments in the final clinical stage – one for the malign melanoma and the second for the treatment of multiple myeloma. We are also preparing the launch of two new products for treating cardiovascular diseases, which are responsible for the highest number of deaths worldwide”, stated Gábor Sztaniszláv, General Manager of Amgen Romania.
Amgen is present on the Romanian market for five years and its 2014 turnover was higher than USD 40 million. The company’s portfolio offers to the Romanian patients targeted therapies for several therapeutic areas: oncology, osteoporosis, nephrology, rare diseases and cardiology.
Last year, the company consolidated its domestic presence by relocating in Romania an important percentage of its division in charge with the monitoring, diagnosis and defense against cyber attacks, Information Security Operation Center.
“We are estimating an investment of USD 6 million in the division by the end of 2016. At present, the division has 40 employees and we want to grow the team by 25% until the end of next year. We have chosen to invest in IT as it is one of the stable and predictible businesses in Romania, in which investments are encouraged. Another decision factor was the fact that Romanians are well-known for their great performance in this field.” added Gábor Sztaniszláv.